A clinical trial of the inhaled Gal-3 inhibitor GB0139 for the treatment of COVID-19 found that it reduced Gal-3 concentrations and other key prognostic biomarkers associated with severe disease, showing potential to reduce the severity of systemic inflammation and cytokine excess in patients with COVID-19 [110]. Here, LGALS3 is linked to COVID-19.